Aktis Oncology Prices IPO at $18 Per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Aktis Oncology, which identifies itself as "a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies," priced its upsized initial public offering of 17.65M shares of its common stock at a price to the public of $18.00 per share. The deal priced at the high-end of the $16.00-$18.00 range. JPMorgan, BofA, Leerink and TD Securities acted as joint book running managers for the offering.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on AKTS
About AKTS
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Helen Kim Acquires 835,000 Shares of AKTS for $15.03M Investment
- Large Transaction: Helen Susan Kim purchased 835,000 shares of AKTS on Monday at $18 each, totaling a $15.03 million investment, marking her first stock purchase in the past 12 months and indicating confidence in the company's future prospects.
- Price Fluctuation: On Tuesday, AKTS reached a high of $23.50, with Kim's investment up approximately 30.6% at the peak, reflecting a positive market response that may attract further investor interest.
- Market Performance: Aktis Oncology Inc saw a 1.8% increase in stock price on Tuesday, indicating a favorable market reaction to Kim's purchase, which could further stabilize the company's stock growth.
- Another Transaction: On the same day, Carl J. Rickertsen bought 5,000 shares of Strategy at $155.88 each, totaling $779,395, marking his first purchase in the past 12 months and demonstrating optimism towards the company.
Continue Reading
Aktis Oncology Closes Upsized IPO Raising $365.4 Million
- Successful IPO: Aktis Oncology completed its initial public offering of 17.65 million shares on January 12, 2026, at an IPO price of $18 per share, indicating strong market demand for its targeted radiopharmaceuticals.
- Additional Share Purchase: Underwriters fully exercised their option to purchase an additional 2.6475 million shares, expected to close on January 14, 2026, further strengthening the company's financial position to support R&D and market expansion.
- Significant Fundraising: The total gross proceeds from the offering are expected to reach approximately $365.4 million, reflecting investor confidence in Aktis's innovative potential in cancer treatment and providing ample funding for future product development.
- Strong Market Debut: Aktis's stock began trading on the Nasdaq Global Select Market on January 9, 2026, under the ticker symbol “AKTS,” marking a successful entry into the capital markets and likely enhancing its brand visibility and competitive position.
Continue Reading